Section 4 of 6
Clinical evidence
117 evidence topics · 24 sources
Study summaries
SL1009-01
Objective
Pivotal evaluation of dichloroacetate
Location and study date
Study design
Eligibility criteria
Age, molecular diagnosis, and phenotype
“Eligible children (6m-17y at entry) have a proven pathological mutation in any PDC component (except DLD) or in a pyruvate dehydrogenase phosphatase isoform, and a clinical phenotype consistent with PDCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Study outcomes
Rationale for using ObsRO motor function as the primary endpoint
At-home function and symptom domains
Original scoring specification
“The ObsRO scoring analysis includes 11 equally-weighted items reflecting at-home functionality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A negative slope indicates functional improvement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA assessment of plasma lactate as a surrogate
Statistical analysis description
Number of participants (Planned and analyzed)
Original evaluable sample-size target
“We took advantage of the rapid pharmacodynamics effects of DCA to construct a double-blind, placebo-controlled, crossover trial of 24 evaluable children, aged 6 months through 17 years, with genetically proven PDCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Original analysis strategy and missing-data plan
Results
Participant disposition
Final randomized-period disposition by treatment sequence
No evidence found.
Baseline characteristics
Efficacy results
FDA primary-analysis treatment difference
Additional motor-function analysis in more seriously affected participants
“Additional analysis suggested by the FDA showed a clinically meaningful, but not statistically significant (p=0.66), improvement in motor function among the most seriously affected subjects, based on ObsRO data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Longer-duration treatment, including the open-label extension
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Most commonly reported adverse reaction occurring in more than 5% of participants
Study limitations
Summary
The trial enrolled 34 participants and did not meet its original primary endpoint. The FDA did not accept the proposed post hoc subgroup analyses or plasma lactate reduction as evidence establishing clinical benefit. The reported p=0.002 motor-function finding included longer treatment and the open-label extension, rather than demonstrating success on the randomized primary comparison. The p=0.66 analysis in more seriously affected participants was also not statistically significant. The report provides an interim disposition update, but not final participant disposition by randomized sequence. The original design publication describes an intention-to-treat strategy and planned imputation, but is not a complete account of the final analysis implementation.
SL1009-02
Objective
Location and study date
Noncontemporaneous cohorts
Study design
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using survival as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
FDA assessment of imputation in the external-control analysis
Additional analyses described in the subsequent resubmission announcement
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
FDA assessment of the proposed comparison
Quantitative results of the additional resubmission analyses
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This comparison reused the SL1009-01 treatment cohort and was not an independent randomized trial. The FDA identified inconsistent imputation, disease-severity imbalance, and an average temporal separation of 18 years between cohorts in its 2025 assessment. These limitations prevent interpreting the sponsor-reported p=0.027 as an established causal survival benefit. The subsequent resubmission announcement describes further analyses, including FDA-requested survival analyses, but this report contains no quantitative results from those additional analyses.
Controlled clinical trial of dichloroacetate for congenital lactic acidosis in children
Objective
Location and study date
Study design
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using global assessment of treatment efficacy as a primary endpoint
Endpoint validation and component weighting
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Pyruvate dehydrogenase deficiency subgroup
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Randomized-period tolerability
Long-term exposure and peripheral nerve findings
“Subject exposure to dichloroacetate totaled 110.42 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conduction velocity decreased and distal latency increased in peroneal nerves.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
Only 11 of the 43 enrolled participants had pyruvate dehydrogenase deficiency, limiting direct applicability of the overall trial result to PDCD. The reported clinical outcomes did not improve. The subsequent open-label follow-up involved 36 participants from the earlier controlled trial and therefore does not represent an independent randomized replication. Peripheral nerve changes during long-term exposure require consideration alongside the short-term tolerability finding.
Dichloroacetate randomized controlled trial in MELAS
Objective
Efficacy of dichloroacetate in MELAS
“To evaluate the efficacy of dichloroacetate (DCA) in the treatment of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The authors hypothesized that chronic cerebral lactic acidosis exacerbates neuronal injury in MELAS and therefore, investigated DCA, a potent lactate-lowering agent, as potential treatment for MELAS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using global assessment of treatment efficacy as the primary endpoint
Endpoint validation
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
Withdrawal of study medication by treatment arm
“During the initial 24-month treatment period, 15 of 15 patients randomized to DCA were taken off study medication, compared to 4 of 15 patients randomized to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical trial was terminated early because of peripheral nerve toxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
No evidence found.
Efficacy results
Between-group difference in mean composite score
Primary outcome and investigator conclusion on benefit
“The mean GATE score was not significantly different between treatment arms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Under these experimental conditions, the authors were unable to detect any beneficial effect.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The findings show that DCA-associated neuropathy overshadows the assessment of any potential benefit in MELAS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The trial enrolled 30 participants with MELAS and the A3243G mutation, not a PDCD population. It was terminated early, and the report documents peripheral neuropathy associated with 17 of 19 medication discontinuations. Its findings provide indirect safety information for chronic dichloroacetate exposure, but do not establish efficacy in PDCD.
Long-term safety of dichloroacetate in congenital lactic acidosis
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using blood lactate as a biochemical outcome
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Pyruvate dehydrogenase complex deficiency subgroup
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose reduction or temporary discontinuation following nerve-conduction changes
Study limitations
Summary
This open-label safety cohort comprised 8 participants, including 3 with PDC deficiency, who had participated in earlier dichloroacetate trials. Treatment continued for 9.7 to 16.5 years. The selected long-term cohort and lack of a concurrent randomized comparison limit causal conclusions about efficacy or comparative safety. Stable laboratory measures did not exclude peripheral nerve findings that prompted dose reduction or temporary discontinuation in 3 participants.
Chronic treatment of mitochondrial disease with dichloroacetate
Objective
Location and study date
Study design
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using blood and cerebrospinal fluid lactate as the biochemical outcomes
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Cohort size and diagnostic heterogeneity
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The study followed 37 participants with various mitochondrial disorders using an open-label format and variable treatment duration. These observations do not provide a randomized estimate of treatment effect in PDCD. Diagnostic heterogeneity and unblinded outcome assessment limit attribution of neurologic changes to dichloroacetate.
Authors’ assessment of efficacy interpretation
PDHX-related neonatal case report
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using blood lactate as a biochemical outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Emergency investigational treatment and clinical response
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The evidence concerns one critically ill neonate with PDHX-related disease. The temporal association between emergency investigational treatment, reduced lactic acid, and stabilization is not a controlled estimate of efficacy. A single case cannot establish comparative benefit, durability, or the frequency of adverse effects.
PDCD case monitored by localized proton magnetic resonance spectroscopy
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using brain lactate as a biochemical outcome
Validation as a predictor of clinical benefit
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This single-case observation links treatment withdrawal with increased brain lactate and recurrent convulsions. It lacks a randomized comparison and cannot establish a general treatment effect, a validated surrogate relationship, or the incidence of treatment-related harm.
Partial pyruvate decarboxylase deficiency treated with dichloroacetate and benzoate
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using serum lactate and pyruvate as the biochemical outcomes
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Age at dichloroacetate administration
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The biochemical reductions were reported in one participant. They do not establish a comparative clinical benefit, long-term neurologic effect, or survival effect. No systematic adverse-event results are included in the retrieved evidence.
Oral dichloroacetate in chronic congenital lactic acidosis
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using blood lactate as a biochemical outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Blood lactate response in the first participant
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Drug accumulation in the first participant
Study limitations
Summary
The report describes two participants of different ages, without a randomized comparator. Reduced blood lactate in the first participant is a biochemical observation, not evidence of a general clinical treatment effect. Reported drug accumulation limits interpretation of biochemical response without considering exposure and toxicity.
Neonatal pyruvate dehydrogenase deficiency with lipoate-responsive lactic acidaemia
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using blood lactate as a biochemical outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The participant received multiple treatment modalities, and the reported lactate response was attributed to lipoic acid rather than isolated dichloroacetate exposure. Death at 1 year 8 months and the absence of a comparator prevent interpreting biochemical improvement as a demonstrated survival benefit.
Transient response to dichloroacetate in an infant with pyruvate decarboxylase deficiency
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using clinical and biochemical response as an outcome measure
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
Dichloroacetate as treatment for congenital lactic acidosis
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using clinical and biochemical response as an outcome measure
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
Dichloroacetate in the treatment of congenital lactic acidosis
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using clinical and biochemical response as an outcome measure
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
PHEMI
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using lactate reduction as the primary endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
Effect of sodium dichloroacetate on human pyruvate metabolism
Objective
Location and study date
No evidence found.
Study design
Single-participant observation
Eligibility criteria
No evidence found.
Treatment
Study outcomes
Rationale for using lactate during exercise as a biochemical outcome
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This is a single-participant pharmacologic observation in mitochondrial encephalomyopathy with congenital lactic acidemia. The report does not provide a randomized comparison or establish that the participant had the target PDCD diagnosis. The exercise-related biochemical response therefore provides indirect evidence rather than an estimate of SL1009 clinical efficacy in PDCD.